1. Stocks
  2. Tatva Chintan Pharma Chem Ltd.
  3. Swot
swot-logo

Tatva Chintan Pharma Chem Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Tatva Chintan Pharma Chem Ltd. has 33 Strengths, 10 Weaknesses, 1 Opportunities and 1 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Add SWOT widget to your site/app

Best results last week in YoY net profit and revenue growth

Benjamin Graham Value Screen

30 Day SMA crossing over 200 Day SMA, and current price greater than open

Expensive Stars (DVM)

Companies with 10% increase in share price over three months, with rising net profit growth

Strong Momentum: Price above short, medium and long term moving averages

Relative Outperformance versus Industry over 1 Month

Momentum Play Screener - Weekly Strategy

Relative Outperformance versus Industry over 1 Year

Stringent DVM Screener - maximize returns

Weekly Strategy: High Momentum Score Stocks (subscription)

New 52 week high today

High Momentum Scores (Technical Scores greater than 50)

Results in the last two days with YoY and QoQ Net Profit Growth

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Companies with rising net profit margins - quarterly as well as TTM basis

Overbought by Money Flow Index (MFI)

Growth in Net Profit with increasing Profit Margin (QoQ)

Companies with Low Debt

Increasing Revenue every Quarter for the past 4 Quarters

Increasing profits every quarter for the past 4 quarters

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

Stock gained more than 20% in one month

Highest Recovery from 52 Week Low

High Volume, High Gain

Top Gainers

High Volume, High Gain

New 52 Week High

Volume Shockers

Stocks near 52 Week High with Significant Volumes

Stocks Outperforming their Industry Price Change in the Quarter

PE higher than Industry PE

PEG greater than Industry PEG

High PE (PE > 40)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Inefficient use of capital to generate profits - RoCE declining in the last 2 years

Inefficient use of shareholder funds - ROE declining in the last 2 years

Inefficient use of assets to generate profits - ROA declining in the last 2 years

Declining Net Cash Flow : Companies not able to generate net cash

Annual net profit declining for last 2 years

Declining profitability: Falling ROCE

FII / FPI or Institutions increasing their shareholding

MFs decreased their shareholding last quarter

Bullish or Bearish Candlestick Strength - Indices

Bullish Engulfing Pattern (Bullish Reversal)

Trendlynes high return technically strong value stocks (subscription)

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Decline in Quarterly Net Profit with falling Profit Margin (YoY)